In this regard, the use of synthetic cannabinoids, such as the mixed CB1/CB2 agonistWin55, 212-2, or the CB2 selective agonist JWH-133, has been shown to improve memory and decrease neuroinflammation in vivo and in vitro models of AD [20,50,51]. This evidence concerns the gene CNR2 and Alzheimer disease.